Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Effect evaluation kit for anti-vascular endothelial growth factor drugs treating wet age-related macular degeneration diseases

An endothelial growth factor, anti-vascular technology, applied in the field of SNP, can solve problems such as poor effect and difficult vision function, and achieve the effect of reducing the risk of drug use, treatment cost, and good clinical application prospects.

Active Publication Date: 2015-06-03
GUANGZHOU KANGRUI BIOLOGICAL PHARMA TECH CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Once wet AMD develops, the course of the disease is rapid, the effect of conventional treatment is not good, and it is difficult to restore the lost visual function to a large extent

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Effect evaluation kit for anti-vascular endothelial growth factor drugs treating wet age-related macular degeneration diseases
  • Effect evaluation kit for anti-vascular endothelial growth factor drugs treating wet age-related macular degeneration diseases
  • Effect evaluation kit for anti-vascular endothelial growth factor drugs treating wet age-related macular degeneration diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 Sample collection and extraction of genomic DNA

[0033] The samples were Caucasian patients (Caucasian patients) clinically diagnosed with wet macular degeneration (AMD), and the number of subjects was 223 cases. The anti-vascular endothelial growth factor drug Bevacizumab) or Ranibizumab was injected into the vitreous, Once a month for 4 months, ophthalmic examination was performed every month, including: best corrected visual acuity (BCVA), evaluated with LogMAR visual acuity chart; central macular thickness (CFT). The level of response was evaluated after 12 months. The best corrected visual acuity (BCVA) was detected by EDTRS table and added a line of visual mark recognition or added 5 letters to be recognized as responders. Those who did not meet the above requirements were regarded as non-responders.

[0034] As shown in Tables 1 and 2, there were 148 eyes of responders to anti-vascular endothelial growth factor drug therapy (among them, 59 eyes were tr...

Embodiment 2

[0041] Example 2 Analysis of VEGFA gene rs943080 polymorphism

[0042] The genotype analysis of VEGFA gene rs943080 variant single nucleotide polymorphism can be detected by existing SNP detection methods, such as Snapshot detection method, sequencing method, restriction fragment length polymorphism analysis method, single-strand conformation polymorphism analysis methods, etc.

[0043] The present invention adopts the Snapshot detection method to detect the single nucleotide polymorphism of VEGFA gene rs943080 variable point:

[0044] 1, get the genomic DNA that embodiment 1 obtains

[0045] 2. Detection of VEGFA gene rs943080 site

[0046] (1) PCR amplification:

[0047] Using the genomic DNA obtained in step 1 as a template, primer pair A (Primer F: 5'-CAACTGAAAGCGGGGAATTA-3'; Primer R: 5'-AGCTCAGCCAAGTGTGGAGT-3';) shown in SEQ ID NO.1~2 as primers, The following systems from Biolab Company were used for amplification (10 μl reaction system):

[0048]

[0049] progr...

Embodiment 3

[0066] Figure 1~3 Genotype map of rs943080 detected for Snapshot. Example 3 Correlation between VEGFA gene rs943080 polymorphism and the effect of anti-vascular endothelial growth factor drugs in the treatment of wet age-related macular degeneration

[0067] According to the detection result of embodiment 2, analyze with statistical method. Statistical methods: SPSS13.0 software was used for analysis, and the Hardy-Weinberg equilibrium test was tested. Quantitative variables were tested by t test, and quality variables were tested by chi-square test. A two-sided P<0.05 was considered statistically significant. The result is as follows:

[0068] 1) Basic clinical data of selected samples

[0069] As shown in embodiment 1 table 1~2.

[0070] 2) Correlation between SNP polymorphisms and anti-vascular endothelial growth factor drugs in the treatment of wet age-related macular degeneration

[0071] Table 3 Correlation between rs943080 polymorphism and disease effect

[0072...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an effect evaluation kit for anti-vascular endothelial growth factor drugs treating wet age-related macular degeneration diseases. The kit includes optional related reagents for detection of VEGFA gene rs943080 variation. The invention also discloses application of VEGFA gene rs943080 variation in preparation of effect evaluation reagents for anti-vascular endothelial growth factor drugs treating wet age-related macular degeneration diseases. The kit provided by the invention can evaluate the treatment effect of anti-vascular endothelial growth factor drugs on wet age-related macular degeneration diseases, and plays an important role in treatment of wet age-related macular diseases.

Description

technical field [0001] The invention relates to the field of SNPs, in particular to SNPs related to the treatment of wet age-related macular degeneration with anti-vascular endothelial growth factor drugs. Background technique [0002] Macular degeneration (AMD) is considered to be a heterogeneous disease characterized by progressive central vision loss and macular retinal pigment epithelial degeneration, and is an important blinding eye disease. Wet macular degeneration disease (wet AMD) often causes serious impairment of vision. The main cause of vision damage is the growth of abnormal new blood vessels under the retina, causing retinal hemorrhage, edema and retinal tissue damage, eventually leading to scar formation, which leads to loss of vision. Once wet AMD develops, the course of the disease is rapid, and the effect of conventional treatment is not good, so it is difficult to restore the lost visual function to a large extent. [0003] Wet AMD can be treated with la...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/68
CPCC12Q1/6883C12Q2600/106C12Q2600/156
Inventor 张康
Owner GUANGZHOU KANGRUI BIOLOGICAL PHARMA TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com